Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Gains from Sales and Divestitures (2021 - 2025)

Legend Biotech filings provide 5 years of Gains from Sales and Divestitures readings, the most recent being $250000.0 for Q2 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 12400.0% to $250000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $250000.0, a 12400.0% increase, with the full-year FY2022 number at $481000.0, down 50.62% from a year prior.
  • Gains from Sales and Divestitures hit $250000.0 in Q2 2025 for Legend Biotech, up from $53000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $481000.0 in Q4 2022 to a low of $2000.0 in Q1 2024.
  • Median Gains from Sales and Divestitures over the past 5 years was $53000.0 (2025), compared with a mean of $102307.7.
  • Biggest five-year swings in Gains from Sales and Divestitures: plummeted 99.1% in 2024 and later skyrocketed 12400.0% in 2025.
  • Legend Biotech's Gains from Sales and Divestitures stood at $54000.0 in 2021, then surged by 790.74% to $481000.0 in 2022, then plummeted by 53.64% to $223000.0 in 2023, then plummeted by 99.1% to $2000.0 in 2024, then skyrocketed by 12400.0% to $250000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $250000.0 (Q2 2025), $53000.0 (Q1 2025), and $2000.0 (Q3 2024) per Business Quant data.